Nuclear Medicine and Cancer Theragnostics: Basic Concepts
Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitt...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/19/3064 |
| _version_ | 1827722710385426432 |
|---|---|
| author | Vasiliki Zoi Maria Giannakopoulou George A. Alexiou Penelope Bouziotis Savvas Thalasselis Andreas G. Tzakos Andreas Fotopoulos Athanassios N. Papadopoulos Athanassios P. Kyritsis Chrissa Sioka |
| author_facet | Vasiliki Zoi Maria Giannakopoulou George A. Alexiou Penelope Bouziotis Savvas Thalasselis Andreas G. Tzakos Andreas Fotopoulos Athanassios N. Papadopoulos Athanassios P. Kyritsis Chrissa Sioka |
| author_sort | Vasiliki Zoi |
| collection | DOAJ |
| description | Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets that are typically dysregulated in different cancers. The major advantages of the theragnostic approach include the elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predictive responses, and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma, and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177. |
| first_indexed | 2024-03-10T21:46:49Z |
| format | Article |
| id | doaj.art-91fcde68bf6a4d90b36242353f509967 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T21:46:49Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-91fcde68bf6a4d90b36242353f5099672023-11-19T14:14:14ZengMDPI AGDiagnostics2075-44182023-09-011319306410.3390/diagnostics13193064Nuclear Medicine and Cancer Theragnostics: Basic ConceptsVasiliki Zoi0Maria Giannakopoulou1George A. Alexiou2Penelope Bouziotis3Savvas Thalasselis4Andreas G. Tzakos5Andreas Fotopoulos6Athanassios N. Papadopoulos7Athanassios P. Kyritsis8Chrissa Sioka9Neurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceNeurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceNeurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceInstitute of Nuclear and Radiological Sciences and Technology, Energy and Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, GreeceSYN Innovation Laboratories SA, 14451 Athens, GreeceDepartment of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, GreeceNeurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceDepartment of Medical Physics, University Hospital of Ioannina, 45500 Ioannina, GreeceNeurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceNeurosurgical Institute, University of Ioannina, 45110 Ioannina, GreeceCancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets that are typically dysregulated in different cancers. The major advantages of the theragnostic approach include the elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predictive responses, and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma, and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.https://www.mdpi.com/2075-4418/13/19/3064theragnosticsnuclear medicinethyroid cancerneuroendocrine tumorsprostate cancercolorectal cancer |
| spellingShingle | Vasiliki Zoi Maria Giannakopoulou George A. Alexiou Penelope Bouziotis Savvas Thalasselis Andreas G. Tzakos Andreas Fotopoulos Athanassios N. Papadopoulos Athanassios P. Kyritsis Chrissa Sioka Nuclear Medicine and Cancer Theragnostics: Basic Concepts Diagnostics theragnostics nuclear medicine thyroid cancer neuroendocrine tumors prostate cancer colorectal cancer |
| title | Nuclear Medicine and Cancer Theragnostics: Basic Concepts |
| title_full | Nuclear Medicine and Cancer Theragnostics: Basic Concepts |
| title_fullStr | Nuclear Medicine and Cancer Theragnostics: Basic Concepts |
| title_full_unstemmed | Nuclear Medicine and Cancer Theragnostics: Basic Concepts |
| title_short | Nuclear Medicine and Cancer Theragnostics: Basic Concepts |
| title_sort | nuclear medicine and cancer theragnostics basic concepts |
| topic | theragnostics nuclear medicine thyroid cancer neuroendocrine tumors prostate cancer colorectal cancer |
| url | https://www.mdpi.com/2075-4418/13/19/3064 |
| work_keys_str_mv | AT vasilikizoi nuclearmedicineandcancertheragnosticsbasicconcepts AT mariagiannakopoulou nuclearmedicineandcancertheragnosticsbasicconcepts AT georgeaalexiou nuclearmedicineandcancertheragnosticsbasicconcepts AT penelopebouziotis nuclearmedicineandcancertheragnosticsbasicconcepts AT savvasthalasselis nuclearmedicineandcancertheragnosticsbasicconcepts AT andreasgtzakos nuclearmedicineandcancertheragnosticsbasicconcepts AT andreasfotopoulos nuclearmedicineandcancertheragnosticsbasicconcepts AT athanassiosnpapadopoulos nuclearmedicineandcancertheragnosticsbasicconcepts AT athanassiospkyritsis nuclearmedicineandcancertheragnosticsbasicconcepts AT chrissasioka nuclearmedicineandcancertheragnosticsbasicconcepts |